1. Home
  2. TGE vs MGNX Comparison

TGE vs MGNX Comparison

Compare TGE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGE

The Generation Essentials Group Class A Ordinary Shares

N/A

Current Price

$1.07

Market Cap

85.8M

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.34

Market Cap

94.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGE
MGNX
Founded
2023
2000
Country
France
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.8M
94.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
TGE
MGNX
Price
$1.07
$1.34
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.20
AVG Volume (30 Days)
374.5K
1.4M
Earning Date
10-20-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.48
N/A
Revenue
$130,212,000.00
$127,626,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.25
N/A
Revenue Growth
316.50
N/A
52 Week Low
$0.78
$0.99
52 Week High
$37.02
$3.64

Technical Indicators

Market Signals
Indicator
TGE
MGNX
Relative Strength Index (RSI) N/A 39.08
Support Level N/A $1.32
Resistance Level N/A $1.47
Average True Range (ATR) 0.00 0.09
MACD 0.00 -0.00
Stochastic Oscillator 0.00 4.11

Price Performance

Historical Comparison
TGE
MGNX

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: